O&G · Sexual and reproductive health — long-acting reversible contraception
Long-acting reversible contraception (LARC)
Also known as LARC · Long-acting reversible contraception · Etonogestrel implant · Nexplanon · Levonorgestrel IUS · Hormonal IUD · Mirena · Copper IUD · Cu-IUD
Exam-exhaustive FRANZCOG fellowship reference on the three LARC methods — etonogestrel subdermal implant, 52 mg levonorgestrel-releasing IUS (Mirena) and the copper IUD — with the insertion technique, bleeding patterns, current durations of use (implant up to 5 years; LNG-IUS up to 8 years for contraception), evidence vs female sterilisation and combined oral contraception (CHOICE Project, Mirena Extension Trial, Bahamondes RCT), and the management of unscheduled bleeding, lost threads and contraceptive failure. ANZ-primary, globally tagged to MRCOG, ABOG, MRCPI.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Pregnancy with a LARC device in place — ectopic risk is relatively higher with LARC failure
- Lost threads: assume expelled until proven otherwise; do not attempt to re-insert, image
- Perforated or migrated IUD — image and refer; do not attempt office retrieval
- Heavy painless vaginal bleeding in LNG-IUS user — re-evaluate, do not auto-blame the method
- Non-palpable implant with prior failed removal attempt — refer for imaging-led retrieval
- Migraine with aura, smoker over 35, postpartum VTE risk — choose LARC, not combined hormonal contraception
You are the gynaecology registrar at a 15-minute contraception counselling appointment. Your patient is a 22-year-old nulliparous woman in a long-term relationship, on the pill and missing it three to four times a month, asking what is "safer than the pill." She has heard the implant makes you bleed and that the IUD is not for people who have not had children. She has class II obesity and a faint family history of thrombosis on her mother's side. You have twenty minutes to take a contraceptive history, choose a method, address her fears and leave her with the right one. This topic is the script for that consultation and every LARC question it generates.[6]
Overview and definition
LARC is the umbrella term for contraceptive methods that require a single administration by a clinician, last years, and work for as long as they are in place — without any daily, weekly or per-coital action by the user. The three marketed methods fall into two mechanical families. [6]
- Subdermal etonogestrel implant — a 4-cm radiopaque rod containing 68 mg etonogestrel, inserted under the skin of the medial upper arm. Releases ENG over up to 5 years (FDA label updated January 2026).[6]
- Levonorgestrel-releasing intrauterine system (LNG-IUS) — a T-shaped polyethylene frame with a hormone reservoir on the vertical stem; the 52 mg device (Mirena in many jurisdictions) is the highest dose and is approved for up to 8 years of contraception; 19.5 mg and 13.5 mg devices are approved for shorter durations.[3][6]
- Copper IUD (Cu-IUD) — a T-shaped polyethylene frame with 380 mm² of copper wound around the vertical stem; non-hormonal, labelled for use up to 10 years in UK and Australian practice, depending on the device label, and used for emergency contraception when inserted within 5 days of unprotected intercourse.[6][8]
The cleanest single-sentence definition used by the U.S. Selected Practice Recommendations is that LARC methods are reversible, user-independent and have "fewer than one user in 100" pregnant in the first year with typical use — a property no short-acting method can match. [6]
References21ShowHide
- [1]Secura GM, Madden T, McNicholas C, Mullersman J, Buckel CM, Zhao Q, Peipert JF Provision of no-cost, long-acting contraception and teenage pregnancy N Engl J Med, 2014.PMID 25271604
- [2]McNicholas C, Madden T, Secura G, Peipert JF The contraceptive CHOICE project round up: what we did and what we learned Clin Obstet Gynecol, 2014.PMID 25286295
- [3]Jensen JT, Lukkari-Lax E, Schulze A, Wahdan Y, Serrani M, Kroll R Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial Am J Obstet Gynecol, 2022.PMID 36096186
- [4]Bahamondes L, Brache V, Meirik O, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls Hum Reprod, 2015.PMID 26409014
- [5]Altshuler AL, Gaffield ME, Kiarie JN The WHO's medical eligibility criteria for contraceptive use: 20 years of global guidance Curr Opin Obstet Gynecol, 2015.PMID 26390246
- [6]Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K, Kortsmit K, Cohen MA, Whiteman MK U.S. Selected Practice Recommendations for Contraceptive Use, 2024 MMWR Recomm Rep, 2024.PMID 39106301
- [7]Tepper NK, Curtis KM, Cox S, Whiteman MK Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection MMWR Morb Mortal Wkly Rep, 2020.PMID 32271729
- [8]Turok DK, Godfrey EM, Wojdyla D, Dermish A, Torres L, Wu SC Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle Hum Reprod, 2013.PMID 23945595
- [9]Sanders JN, Turok DK, Royer PA, Thompson IS, Gawron LM, Storck KE One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception Contraception, 2017.PMID 28596121
- [10]Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience Hum Reprod, 2012.PMID 22570193
- [11]Mohr-Sasson A, Dalal L, Bhalwal A The association between BMI and continuity of etonogestrel (ENG)-releasing implant Int J Gynaecol Obstet, 2024.PMID 38712353
- [12]Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index Contraception, 2017.PMID 28126541
- [13]Dragoman MV, Gaffield ME The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review Contraception, 2016.PMID 26874275
- [14]Bahamondes L, Bottura BF, Bahamondes MV, Gonçalves MP, Correia VM, Espejo-Arce X Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic Hum Reprod, 2014.PMID 25085802
- [15]Zapata LB, Pazol K, Dehlendorf C, Curtis KM, Malcolm NM, Rosmarin RB Contraceptive Counseling in Clinical Settings: An Updated Systematic Review Am J Prev Med, 2018.PMID 30342631
- [16]Dermish AI, Turok DK, Jacobson JC, Flores ME, McFadden M, Burke K Failed IUD insertions in community practice: an under-recognized problem? Contraception, 2013.PMID 22979954
- [17]Fok WK, Blumenthal PD Update on emergency contraception Curr Opin Obstet Gynecol, 2016.PMID 27676405
- [18]Bateson D, Butcher BE, Donovan C, Farrell L, Kovacs G, Mezzini T Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis Aust Fam Physician, 2016.PMID 27051991
- [19]ESHRE Capri Workshop Group Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review Hum Reprod, 2015.PMID 25678571
- [20]Glasier A Emergency contraception: clinical outcomes Contraception, 2013.PMID 23040128
- [21]Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices Obstet Gynecol, 2017.PMID 29064972